Provided by Tiger Trade Technology Pte. Ltd.

RAPT Therapeutics, Inc.

33.18
-0.8500-2.50%
Volume:351.50K
Turnover:11.67M
Market Cap:919.45M
PE:-5.03
High:35.17
Open:34.14
Low:31.70
Close:34.03
52wk High:42.39
52wk Low:5.67
Shares:27.71M
Float Shares:13.26M
Volume Ratio:0.90
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5969
EPS(LYR):-25.4880
ROE:-85.37%
ROA:-51.35%
PB:6.05
PE(LYR):-1.30

Loading ...

TD Cowen Initiates Coverage on RAPT Therapeutics With Buy Rating

MT Newswires Live
·
19 mins ago

RAPT Therapeutics Chief Medical Officer William Ho to Depart at Year-End

Reuters
·
Nov 29

J.P. Morgan Remains a Buy on RAPT Therapeutics (RAPT)

TIPRANKS
·
Nov 12

Rapt Therapeutics Unveils Pipeline Progress for Ozureprubart in Allergic Diseases

Reuters
·
Nov 11

RAPT Therapeutics Inc expected to post a loss of 88 cents a share - Earnings Preview

Reuters
·
Nov 07

RAPT Therapeutics : Barclays Cuts Target Price to $56 From $58

THOMSON REUTERS
·
Nov 07

Rapt Therapeutics shares ‘exceptionally compelling,’ says Clear Street

TIPRANKS
·
Nov 07

Promising Clinical and Financial Developments Drive Buy Rating for RAPT Therapeutics

TIPRANKS
·
Nov 07

Buy Rating for RAPT Therapeutics Driven by Promising Ozureprubart Data and Strategic Growth Plans

TIPRANKS
·
Nov 07

RAPT Therapeutics Q3 EPS $(0.65) Beats $(0.80) Estimate

Benzinga
·
Nov 06

Rpt- RAPT Therapeutics Q3 EPS USD -0.65

THOMSON REUTERS
·
Nov 06

Rapt Therapeutics Q3 net loss narrows as R&D costs drop

Reuters
·
Nov 06

RAPT Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $72 From $27

THOMSON REUTERS
·
Oct 27

Clear Street positive on Rapt Therapeutics into food allergy study

TIPRANKS
·
Oct 27

Guggenheim Initiates RAPT Therapeutics at Buy With $70 Price Target

MT Newswires Live
·
Oct 27

RAPT Therapeutics Initiates Prestige Phase 2B Clinical Trial of Ozureprubart (Rpt904) in Patients With Food Allergies

THOMSON REUTERS
·
Oct 27

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

GlobeNewswire
·
Oct 27

LifeSci Capital Remains a Buy on RAPT Therapeutics (RAPT)

TIPRANKS
·
Oct 25

Leerink Partners Keeps Their Buy Rating on RAPT Therapeutics (RAPT)

TIPRANKS
·
Oct 22

BRIEF-RAPT Therapeutics Announces Pricing Of Public Offering Of 8.3 Million Shares At $30.00 Each

Reuters
·
Oct 22